SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
Lunedì 15 febbraio 2021
ca. 1 min. di lettura
Journal and Affiliations:
medRxiv, 15 febbraio 2021
Anna De Marco, Humabs Biomed, Bellinzona
Jessica Bassi, Humabs Biomed, Bellinzona
Dora Pinto, Humabs Biomed, Bellinzona
Chiara Silacci Fregni, Humabs Biomed, Bellinzona
Siro Bianchi, Humabs Biomed, Bellinzona
Katja Culap, Humabs Biomed, Bellinzona
Stefano Jaconi, Humabs Biomed, Bellinzona
Elisabetta Cameroni, Humabs Biomed, Bellinzona
Matteo Samuele Pizzuto, Humabs Biomed, Bellinzona
Antonio Lanzavecchia, Humabs Biomed, Bellinzona
Luca Piccoli, Humabs Biomed, Bellinzona
Davide Corti, Humabs Biomed, Bellinzona
Alessandra Franzetti Pellanda, Medicina interna e Malattie infettive, Clinica Luganese Moncucco, Lugano
Tags:
B1.1.7 variant
mRNA-based vaccine
SARS-CoV-2
Authors:
Alessandra Franzetti Pellanda
Anna De Marco
Antonio Lanzavecchia
Chiara Silacci Fregni
Davide Corti
Dora Pinto
Elisabetta Cameroni
Jessica Bassi
Katja Culap
Luca Piccoli
Matteo Samuele Pizzuto
Siro Bianchi
Stefano Jaconi